Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance

Soleno Therapeutics (NASDAQ:SLNO) is one of the 17 biotechnology stocks with more than 50% upside.

On January 20, the price target on Soleno Therapeutics (NASDAQ:SLNO) was increased from $110 to $120 by Ram Selvaraju from H.C. Wainwright. He also reaffirmed his Buy rating on the stock, which, as per his forecasts, offers an upside potential of almost 211%. The analyst based his rating on the company’s impressive sales figures, which continue to beat estimates.

Likoper/Shutterstock.com

On January 20, Wells Fargo analyst Derek Archila maintained an Overweight rating on Soleno Therapeutics (NASDAQ:SLNO). He also raised the price target from $106 to $114, leading to a revised upside potential of 195%.

Archila highlighted fourth-quarter earnings for Vykat extended-release that surpassed expectations. Although new PSFs fell short, management’s recent remarks confirmed a target of approximately 250 new starts per quarter, excluding the effects of any seasonal factors. Given the company’s strong cash flow profile, the analyst views shares as currently undervalued.

Soleno Therapeutics (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company developing novel therapies for rare diseases such as Prader-Willi Syndrome. Its leading product is Diazoxide Choline Extended-Release tablets, VYKAT XR. The company began commercialization of VYKAT XR in April 2025, following FDA approval.

While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.